MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Viking Therapeutics Inc

Cerrado

SectorSanidad

25.68 7.67

Resumen

Variación precio

24h

Actual

Mínimo

23.51

Máximo

25.74

Métricas clave

By Trading Economics

Ingresos

-10M

-35M

BPA

-0.32

Empleados

36

EBITDA

-9.6M

-46M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+319.28% upside

Dividendos

By Dow Jones

Próximas Ganancias

23 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-375M

2.9B

Apertura anterior

18.01

Cierre anterior

25.68

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

180 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Viking Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 feb 2025, 10:30 UTC

Principales Noticias

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

23 dic 2024, 15:04 UTC

Principales Noticias

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 dic 2024, 14:53 UTC

Principales Noticias

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

4 nov 2024, 12:22 UTC

Principales Noticias

Viking Therapeutics Jumps On Latest Obesity Drug Data -- IBD

4 nov 2024, 12:00 UTC

Principales Noticias

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

4 nov 2024, 10:11 UTC

Acciones populares

Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel -- WSJ

4 oct 2024, 12:01 UTC

Principales Noticias

As Weight-Loss Drugs Battle, Upstart Viking -2-

4 oct 2024, 12:01 UTC

Principales Noticias

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

20 sept 2024, 13:55 UTC

Principales Noticias

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

25 jul 2024, 15:03 UTC

Ganancias

Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill -- Barrons.com

Comparación entre iguales

Cambio de precio

Viking Therapeutics Inc previsión

Precio Objetivo

By TipRanks

319.28% repunte

Estimación a 12 Meses

Media 100.25 USD  319.28%

Máximo 164 USD

Mínimo 38 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Viking Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

16 ratings

15

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

23.27 / 26.09Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

180 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.